Quick summary: LEMTRADA (alemtuzumab) - Risk of Autoimmune Hepatitis, Haemophagocytic Lymphohistiocytosis, and Associated Serious Cardiovascular Reactions .
LEMTRADA (alemtuzumab) - Risk of Autoimmune Hepatitis, Haemophagocytic Lymphohistiocytosis, and Associated Serious Cardiovascular Reactions
Recommended action: compare your product with the official notice and follow the instructions published by the official source.
Recall details
Quick summary: LEMTRADA (alemtuzumab) - Risk of Autoimmune Hepatitis, Haemophagocytic Lymphohistiocytosis, and Associated Serious Cardiovascular Reactions .
Affected product details
Structured information extracted from the official recall notice. Confirm the identifiers and instructions in the original notice.
Affected products
Issue
New safety information from post-market use of LEMTRADA has been reported and includes fatal cases, cardiovascular adverse events that have occurred shortly after LEMTRADA infusions, and immune-mediated adverse reactions. The LEMTRADA Canadian Product Monograph has been updated to include a revised indication for use and safety information.
What you should do
Additional official information
Contains information licensed under the Open Government Licence – Canada. SafetyPulse is independent of the Government of Canada.
Frequently asked questions
Answers based on the official recall notice.
Product images
Official product images from Health Canada.
Starting...
Explore more
Related recalls
Similar recalls and safety notices.